Part I. SARS-CoV-2 triggered ‘PANIC’1 attack in severe COVID-19

[1]  P. Anfinrud,et al.  The airborne lifetime of small speech droplets and their potential importance in SARS-CoV-2 transmission , 2020, Proceedings of the National Academy of Sciences.

[2]  F. J. Carod-Artal.  Neurological complications of coronavirus and COVID-19. , 2020, Revista de neurologia.

[3]  F. J. Carod-Artal,et al.  Neurological complications of coronavirus and COVID-19. , 2020, Revista de neurologia.

[4]  A. Rodríguez-Antigüedad,et al.  Emergency room neurology in times of COVID‐19: malignant ischaemic stroke and SARS‐CoV‐2 infection , 2020, European journal of neurology.

[5]  F. Chigr,et al.  Comment on “The neuroinvasive potential of SARS‐CoV‐2 may play a role in the respiratory failure of COVID‐19 patients” , 2020, Journal of medical virology.

[6]  Amit Kumar Srivastava,et al.  Is the Collapse of the Respiratory Center in the Brain Responsible for Respiratory Breakdown in COVID-19 Patients? , 2020, ACS chemical neuroscience.

[7]  A. Harky,et al.  COVID-19 and Multiorgan Response , 2020, Current Problems in Cardiology.

[8]  Surajit Ghosh,et al.  Neurological Insights of COVID-19 Pandemic , 2020, ACS chemical neuroscience.

[9]  J. Finsterer,et al.  Causes of hypogeusia/hyposmia in SARS‐CoV2 infected patients , 2020, Journal of medical virology.

[10]  Xiaopei Xu,et al.  Neurological manifestations of the coronavirus (SARS-CoV-2) pandemic 2019–2020 , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.

[11]  G. Whittaker,et al.  Phylogenetic Analysis and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct and Proteolytically Sensitive Activation Loop , 2020, Journal of Molecular Biology.

[12]  J. Benito-León,et al.  Miller Fisher syndrome and polyneuritis cranialis in COVID-19 , 2020, Neurology.

[13]  A. Asadi-Pooya,et al.  Central nervous system manifestations of COVID-19: A systematic review , 2020, Journal of the Neurological Sciences.

[14]  L. Mao,et al.  Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. , 2020, JAMA neurology.

[15]  R. Kahwash,et al.  Will Complement Inhibition be the New Target in Treating COVID-19 Related Systemic Thrombosis? , 2020, Circulation.

[16]  Abdul Mannan Baig,et al.  Neurological manifestations in COVID‐19 caused by SARS‐CoV‐2 , 2020, CNS neuroscience & therapeutics.

[17]  Gian Paolo Rossi,et al.  Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients , 2020, eLife.

[18]  N. Vaninov.  In the eye of the COVID-19 cytokine storm , 2020, Nature Reviews Immunology.

[19]  P. Marchetti,et al.  Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. , 2020, European review for medical and pharmacological sciences.

[20]  B. Menon,et al.  Protected Code Stroke , 2020, Stroke.

[21]  A. Rudd,et al.  Challenges and Potential Solutions of Stroke Care During the Coronavirus Disease 2019 (COVID-19) Outbreak , 2020, Stroke.

[22]  A. Nath.  Neurologic complications of coronavirus infections , 2020, Neurology.

[23]  G. G. Onischenko,et al.  A new threat from an old enemy: Re-emergence of coronavirus (Review) , 2020, International journal of molecular medicine.

[24]  Yan Zhao,et al.  The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China , 2020, Clinical Immunology.

[25]  S. Antinori,et al.  COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? , 2020, Clinical and experimental rheumatology.

[26]  X. Bian,et al.  [A pathological report of three COVID-19 cases by minimally invasive autopsies]. , 2020, Zhonghua bing li xue za zhi = Chinese journal of pathology.

[27]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[28]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[29]  Tsutomu Hashikawa,et al.  The neuroinvasive potential of SARS‐CoV2 may play a role in the respiratory failure of COVID‐19 patients , 2020, Journal of medical virology.

[30]  Jiyuan Zhang,et al.  Pathological findings of COVID-19 associated with acute respiratory distress syndrome , 2020, The Lancet Respiratory Medicine.

[31]  Chuan Qin,et al.  Dysregulation of immune response in patients with COVID-19 in Wuhan, China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  Suxin Wan,et al.  Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP) , 2020, medRxiv.

[33]  Matthew R. McKay,et al.  Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies , 2020, bioRxiv.

[34]  T. Burki.  Coronavirus in China , 2020, The Lancet Respiratory Medicine.

[35]  Tiantian Han,et al.  Coronavirus infections and immune responses , 2020, Journal of medical virology.

[36]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[37]  G. Gao,et al.  A Novel Coronavirus Genome Identified in a Cluster of Pneumonia Cases — Wuhan, China 2019−2020 , 2020, China CDC weekly.

[38]  M. Cetron,et al.  First travel-related case of 2019 novel coronavirus detected in United States : press release, Tuesday, January 21, 2020 , 2020 .

[39]  C. Patriquin,et al.  Eculizumab and Beyond: The Past, Present, and Future of Complement Therapeutics. , 2019, Transfusion medicine reviews.

[40]  K. Nichols,et al.  The Immunology of Macrophage Activation Syndrome , 2019, Front. Immunol..

[41]  Lisa E. Gralinski,et al.  Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis , 2018, mBio.

[42]  J. Rini,et al.  Axonal Transport Enables Neuron-to-Neuron Propagation of Human Coronavirus OC43 , 2018, Journal of Virology.

[43]  Shin C. Beh,et al.  High-dose methotrexate with leucovorin rescue: For monumentally severe CNS inflammatory syndromes , 2017, Journal of the Neurological Sciences.

[44]  Lisa E. Gralinski,et al.  Genome Wide Identification of SARS-CoV Susceptibility Loci Using the Collaborative Cross , 2015, PLoS genetics.

[45]  V. Frémeaux-Bacchi,et al.  Complement System Part I – Molecular Mechanisms of Activation and Regulation , 2015, Front. Immunol..

[46]  Lubka T. Roumenina,et al.  Complement System Part II: Role in Immunity , 2015, Front. Immunol..

[47]  Susanna K. P. Lau,et al.  Middle East Respiratory Syndrome Coronavirus: Another Zoonotic Betacoronavirus Causing SARS-Like Disease , 2015, Clinical Microbiology Reviews.

[48]  Yan Li,et al.  The role of C5a in acute lung injury induced by highly pathogenic viral infections , 2015, Emerging Microbes & Infections.

[49]  Alain Le Coupanec,et al.  Human coronaviruses: Viral and cellular factors involved in neuroinvasiveness and neuropathogenesis , 2014, Virus Research.

[50]  M. Titécat,et al.  Distinct Immune Response in Two MERS-CoV-Infected Patients: Can We Go from Bench to Bedside? , 2014, PloS one.

[51]  Wuding Zhou,et al.  The role of anaphylatoxins C3a and C5a in regulating innate and adaptive immune responses. , 2009, Inflammation & allergy drug targets.

[52]  Kui Li,et al.  Severe Acute Respiratory Syndrome (SARS) Coronavirus-Induced Lung Epithelial Cytokines Exacerbate SARS Pathogenesis by Modulating Intrinsic Functions of Monocyte-Derived Macrophages and Dendritic Cells , 2008, Journal of Virology.

[53]  David K. Meyerholz,et al.  Severe Acute Respiratory Syndrome Coronavirus Infection Causes Neuronal Death in the Absence of Encephalitis in Mice Transgenic for Human ACE2 , 2008, Journal of Virology.

[54]  P. Factor,et al.  Clinical review: Airway hygiene in the intensive care unit , 2008, Critical care.

[55]  Sergio E. Baranzini,et al.  Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets , 2008, Nature.

[56]  David K. Meyerholz,et al.  Lethal Infection of K18-hACE2 Mice Infected with Severe Acute Respiratory Syndrome Coronavirus , 2006, Journal of Virology.

[57]  H. Tsutsumi,et al.  Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections† , 2006, Journal of medical virology.

[58]  N. Zhong,et al.  Detection of Severe Acute Respiratory Syndrome Coronavirus in the Brain: Potential Role of the Chemokine Mig in Pathogenesis , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[59]  Bo Zhang,et al.  Multiple organ infection and the pathogenesis of SARS , 2005, The Journal of experimental medicine.

[60]  Jing Li,et al.  Analysis of Serum Cytokines in Patients with Severe Acute Respiratory Syndrome , 2004, Infection and Immunity.

[61]  Qingling Zhang,et al.  Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS‐CoV) in SARS patients: implications for pathogenesis and virus transmission pathways , 2004, The Journal of pathology.

[62]  Xiaojun Xu,et al.  Immunological responses against SARS-coronavirus infection in humans. , 2004, Cellular & molecular immunology.

[63]  Junya Fukuoka,et al.  Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore , 2003, Human Pathology.

[64]  W. Travis,et al.  Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore 1 1 This is a US government work. There are no restrictions on its use. , 2003, Human Pathology.

[65]  S. Perlman,et al.  Effect of olfactory bulb ablation on spread of a neurotropic coronavirus into the mouse brain , 1990, The Journal of experimental medicine.

[66]  D. Diz,et al.  Identification of angiotensin-(1-7) in rat brain. Evidence for differential processing of angiotensin peptides. , 1989, The Journal of biological chemistry.

[67]  H. Müller-Eberhard,et al.  C4a: the third anaphylatoxin of the human complement system. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[68]  W. Whimster.  The microanatomy of the alveolar duct system , 1970, Thorax.

[69]  P. Ward,et al.  Role of C3, C5 and anaphylatoxin receptors in acute lung injury and in sepsis. , 2012, Advances in experimental medicine and biology.

[70]  E. Lazartigues,et al.  Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system. , 2007, American journal of physiology. Regulatory, integrative and comparative physiology.

[71]  P. Ward,et al.  Role of C5a in inflammatory responses. , 2005, Annual review of immunology.

[72]  XiaojunXu,et al.  Immunological Responses against SARS-Coronavirus Infection in Humans , 2004 .